Common heart drugs recalled due to contamination with possible carcinogen

Henrietta Strickland
July 12, 2018

Canada is one of 22 countries affected by a recall of a common drug for treating high blood pressure and prevention of heart attacks and stroke because of contamination with a potential carcinogen.

This recall has been issued following indications of the presence of an undesirable impurity N-nitrosodimethylamine (NDMA) in the valsartan active ingredient, which is manufactured by a facility in China.

Valsartan is a medicine used for the treatment of hypertension to prevent related cardiovascular complications. For example, Swiss company Novartis informed the ministry that their products containing valsartan are not impacted because these products do not contain the ingredient from external suppliers.

The recall affects several drugs containing the ingredient valsartan, Health Canada announced Tuesday.

Some of these drugs are also used in patients who have had heart failure or a recent heart attack.

Health Canada says patients taking the drug should check with their pharmacists to learn if their medicine is being recalled.

Valsartan should continue to be taken unless users have alternative medicine available, the Public Health Superintendence said today.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER